Mucosal dendritic cells (DCs) are very important in the process of antigen presentation to T cells, playing a key role in the induction of primary and secondary immune responses.
Taken together our data suggest the possibility to use pidotimod as adjuvant molecule to facilitate the activation of the innate immune system as well as to promote an effective mucosal and systemic immune response.
Introduction
Mucosa constitutes the main entry site for the majority microbial pathogens. A large and highly specialized innate and adaptative mucosal immune system protects the mucosal surfaces and the body interior from potential injuries. The cells of local immune system are accumulated in or transit between various mucosa-associated lymphoid tissues (MALT). The MALT represents a highly compartmentalized immunological system which acts almost independently from the systemic one. Immune responses in mucosal tissues are governed by the nature of the antigen, the type of antigen presenting cells (APCs) involved and the local environment. In mucosal sites the antigens can be directly captured by professional APCs, which include dendritic cells, B lymphocytes and macrophages, for presentation to T cell.
Mucosal dendritic cells are very important in the process of antigen presentation, serve as a link between the innate and adaptive immune system 1,2 and govern both initiation and polarization of adaptive immunity 3. Immature DCs patrol as sentinels in almost every nonlymphoid tissue and organ, have a highly developed capacity to capture antigens, but a poor T cell-stimulatory activity 4,5. Upon recognition of pathogens, DCs undergo phenotypic and functional changes to differentiate into mature stage resulting in the up-regulation of specific proteins for antigen presentation and T cell activation, including the major histocomplex (MHC) and the co-stimulatory molecules CD40, CD80, and CD86. They also up-regulate CCR7, a chemotactic receptor that induces DCs to travel through the blood stream to the spleen or through the lymphatic system to a lymph node. Here they act as antigen-presenting cells, prime naive antigen-specific T cells and drive their differentiation. The results of clinical application indicate that maturation status of DCs plays a pivotal role in initiating and guiding the immune response 6. Therefore, it is important to identify reagents to use in promoting DCs maturation and differentiation.
For this reason it's important to understand how to mobilize mucosal DCs to prime robust protective immunity against mucosally acquired infections especially for children and elderly people, who may present with a poor or even deficient immune response.
In the first two years of life children haven't got a completely formed immune system yet and, especially in early childhood, they are also subjected to recurrent infections, essentially in the respiratory tract, and they need prophylactic and therapeutic immunomodulant treatments of diseases. Also elderly people show a higher susceptibility to infections 7,8 and a reduced response to vaccination, particularly against influenza virus 9,10. This is essentially due to a reduced ability of the innate immune system to properly respond to dangerous signals and to organize a correct antigen processing and presentation 11. The result is a decreased production of cytokines and chemokines, which are able to create a suitable microenvironment to generate a crosstalk between innate and adaptive immunity 12,13.
The co-administration of immune modulatory drugs represents a widely used strategy to increase mucosal  and systemic  immune response 1416 and to favour the development of stronger and broader immune responses engaging both the humoral and cellular immunity. Molecules with immunomodulatory activity and adjuvant properties at the mucosal level are few to date and there is an urgent need for new drugs displaying such features.
Pidotimod (3-L-pyroglutamyl-L-thiaziolidine-4carboxylic acid) is a synthetic substance with important immunomodulatory properties in vitro and in vivo 17,18. Pidotimod is able to induce a protective effect against infectious processes as demonstrated in many controlled clinical trials of experimental bacterial and viral infection. In particular, administration of pidotimod by oral route increases resistance to viral infections 19 and makes the activity of antiviral drugs more effective for recurrent respiratory infections (RRI) in pediatric patients 2022. However the effects of pidotimod on cellular response are still poorly characterized, and there is little information concerning the general mechanism of action of this synthetic compound.
In this study, we investigated whether pidotimod could induce the maturation of human monocyte-derived immature DCs, influence the cytokines production from MDDCs and induce proliferation and differentiation of CD4 + naïve T cells towards a Th1-polarizing phenotype. Moreover, we investigated the ability of pidotimod to act as adjuvant in mice challenged intranasally with a model antigen. Cells were incubated at 4 °C for 10 min, washed twice in MACS buffer (PBS 1X, 0.5% BSA, 2 mM EDTA) and isolated by an autoMACS separator (Miltenyi Biotech, Bergisch Gladbach, Germany), according to the manufacturer's protocol. CD14 + monocytes (purity > 98%) were washed and resuspended in RPMI 1640 (Sigma) containing penicillin (100 U/ml), streptomycin (100 μg/ml), L-glutamine (2 mM) and 10% heat inactivated FCS (Euroclone, Celbio, Milan, Italy), then seeded in 48-well plates (Falcon, BD Biosciences) and supplemented with 500 U/ml of rh-IL-4 and 800 U/ml of GM-CSF (R&D Systems, Minneapolis, MN, USA). After 3 days the medium was changed with complete medium containing cytokines. After 6 days of culture, the cells were harvested, pooled together and counted. On the 6 th day immature DCs were stimulated by using 1µg/ml of LPS from Escherichia coli 026:B6 (Sigma) or pidotimod (1 µg/ml). In some experiments pidotimod (1g/ml) was also used in combination with LPS (10ng/ml) and a combination of LPS (10 ng/ml) and IFN-γ (100ng/ml) was used as positive control. The supernatants were collected after 24 h and kept frozen at −80°C for cytokine quantification assays.
Materials and Methods

Monocyte derived DC (MDDCs
The absence of endotoxin contamination (0.25 endotoxin unit/500 μg of pidotimod stock solution) in the pidotimod preparation was assessed by Limulus amoebocyte assay, Associates of Cape Cod Inc, Falmouth, MA). 
Immunophenotyping analysis of MDDCs
Measurement of cytokines
Culture supernatants of iMDDCs were assayed for the presence of monocyte chemoattractant protein (MCP)-1, tumor necrosis factor (TNF)- and interleukin (IL)-12p70 using ELISA kits purchased from Endogen (Boston, MA) according to the manufacturer's instructions. 
Measurement of intracellular cytokines
The acquisition of cell functional polarization of CD4 In some experiments spleens and bone marrow from shinbone and thigh bone were collected and grown in RPMI 1640 supplemented with 10% fetal calf serum, 100 U/ml of penicillin, 50 µg/ml of streptomycin, 5 x 10 -5 M 2-mercaptoethanol and 1 mM L-glutamine (GIBCO BRL, Karlsruhe, Germany) and were maintained at 37 °C in a humidified 5% CO 2 atmosphere.
Detection of anti-OVA antibodies
The amount of specific antibodies anti-OVA was determined by ELISA. Briefly, 96-well Immuno MaxiSorp assay plates (Nunc, Roskilde, Denmark) were coated overnight at 4 °C with 100 µl of OVA at 5 µg/ml in carbonate buffer (pH 9.6). After blockage of wells, the plates were washed and further incubated with 100 µl of serial two-fold dilutions of sera for 1 h at 37 °C. After four washes, anti-mouse biotinylated detection antibody (Sigma Chemie, Deisenhofen, Germany), was added in each well. The plates were further incubated for 1 h at 37 °C. After the plates were washed, peroxidaseconjugated streptavidin (PharMingen) was added and the plates were incubated at room temperature for 45 min. After four washes, the reactions were developed by using ABTS 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid) in 0.1 M citratephosphate buffer (pH 4.35) containing 0.01% H 2 O 2 and the absorbance was read at a wavelength of 405 nm. The results were expressed as mean ± standard errors of the means (SEMs) for each group.
Detection of Ig-producing cells by ELISPOT assay.
The total number of antigen-specific IgG secreting cells was determined 2 months after the last immunization by enzyme-linked immunospot (ELISPOT) assay. Briefly, polyvinylidene difluoride (PVDF) plates (Millipore, Bedford, MA) were coated with either 100 µl/well of isotype-specific antibodies (Sigma, Germany) at a concentration of 5 µg/ml or OVA antigen at 5 µg/ml in carbonate buffer, pH 9.6) to determine total and antigen-specific antibodies respectively. Different concentrations of splenocytes and bone marrow cells were incubated in quadruplicate for 6 h. Then, the plates were washed, 100 µl of the corresponding biotinylated detection antibody (Sigma) was added and the plates were further incubated overnight at 4 °C.
After several washes, the plates were incubated for 1 h with 100 µl/well of peroxidaseconjugated streptavidin (BD-Pharmingen, Germany). Spots were developed using 3-amino-9-ethylcarbazole (Sigma) in 0.1 M acetate-buffer (pH 5.0) and 0.05% H 2 O 2 (30%). Spots were scanned with an ImmunoSpot series 3A Analyzer and were counted by using ImmunoSpot image analyzer software (version 3.2; Cellular Technology, Ltd.).
Detection of IFN- producing cells by ELISPOT assay.
The number of IFN- secreting spleen and bone marrow cells was determined by ELISPOT for well and were incubated in quadruplicate in the absence or presence of different concentrations of the MHC class Irestricted dominant, subdominant and cryptic OVA peptides (SIINFEKL, KVVRFDKL and CFDVFKEL respectively). After 16 h of culture, the cells were removed and the local production of IFN- was detected by using anti-IFN- biotinylated antibody, which was developed by addition of peroxidase-conjugated streptavidin and substrates, as described above.
Determination of lymphocyte-mediated cytotoxicity in vivo.
In order to determine the lymphocyte-mediated cytotoxicity, suspensions of splenocytes from naïve C57BL/6 mice were split into two equal portions. One portion was labeled with high concentration 1µM of carboxyfluorescein-succinyl-ester (CFSE; Molecular Probes) and the other with a low concentration (0.1µM) of CFSE. Half of each cell population was then stained with 10 µM of CMTMR (Molecular Probes). The splenocytes were further pulsed for 
Statistical Analysis
The statistical significance of the differences between the two groups examined was determined by the means and standard deviation using Student's t-test and between three or more groups by the one-way analysis of variance (ANOVA). Differences were considered significant at P  0.05.
Results
Pidotimod induces maturation of MDDCs.
In order to investigate the effect of pidotimod on the maturation of MDDCs, human CD14 
Cytokine production by MDDCs in response to pidotimod treatment.
DCs play an important role in T cell-mediated immune response via secretion of different cytokine profiles. In particular we focused on MCP-1 and TNF-since they represent important local inflammation mediators. In fact, these molecules are able to activate the vascular endothelium and increase its permeability, increase the recruitment of inflammatory cells and the synthesis of other cytokines. Experiments were performed to assess the capability of pidotimod to modulate the production of these pro-inflammatory molecules by iMDDC. iMDDCs, generated as described before, were cultured for 24 h in both the presence and absence of pidotimod (1g/ml) and supernatant tested for the presence of MCP-1 and TNF- by quantitative ELISA. As shown in Fig. 2 , pidotimod-treated dendritic cells produced significantly larger amounts of MCP-1 and TNF-α than untreated cells, the increase was approximately of 180% and 450% for MCP-1 and TNF- respectively (p<0.01) These results indicate that pidotimod exerts a potent activity on DC function by inducing them to release high amounts of pro-inflammatory molecules MCP-1 and TNF-α cytokines. We found that naive T cells co-cultured with pidotimod-treated iMDDCs secreted substantially higher amounts of the Th1 cytokine IFN- (Fig. 3B ) (p<0.01) than cells cocultured with mock-treated iMDDCs. This finding provides evidence that pidotimod drives DCs to stimulate T cell differentiation towards a Th1 phenotype.
Pidotimod-treated DCs induce proliferation and polarization of co-cultured CD4
Because the level of IL-12 production by myeloid DCs during activation of naïve Th cells is a major factor driving the development of Th1 cells, we also evaluated the effects of pidotimod on bioactive IL-12p70 production by iMDDCs. We tested the supernatants of iMDDCs for the presence of IL-12 by quantitative ELISA after 24h of culture with pidotimod (1g/ml) either as a unique stimulus or in combination with the classical maturation stimulus LPS (10ng/ml).
In fact, it is known that is especially important at the onset of a primary immune response the need for a second signal to induce IL-12 production 25,26. As positive control we cultured iMDDCs in the presence of LPS (10ng/ml) and IFN-γ (100ng/ml) and, as expected, we observed a consistent secretion of IL-12p70. Surprisingly, DCs didn't show enhanced IL12p70 production when treated with pidotimod alone or in combination with LPS (data not shown). This suggests that the ability of pidotimod to induce the development of Th1-inducing DCs is due to the existence of an alternative Th1-driving mechanism.
Intranasal immunization with OVA co-administered with pidotimod results in the elicitation of strong antigen-specific antibody responses in serum.
The upper airway mucosa of humans contains a dense network of dendritic APCs both in the epithelium and in the lamina propria 27. These mucosal DCs express an immature phenotype with low levels of costimulatory molecules and are functionally characterized by high antigen-capturing and low antigen-presenting capacity 28. (Fig.   4C-D) . In contrast, co-administration of the OVA protein with pidotimod triggered splenocytes and bone marrow cells to produce IFN- (Fig. 4B) .This result suggests that intranasal injection of a model antigen with pidotimod results in an OVA specific Th1 immune response.
Intranasal immunization with pidotimod results in the production of OVA-specific
IgG from splenocytes and bone marrow cells.
It is known that after initial contact with an antigen, plasmablasts generate a short humoral immune response. However, most antibodies secreting cells (ASCs), generated by a second contact with the antigen, leave the secondary lymphoid organs to move towards bone marrow, mucosal-associated tissues and chronically inflamed tissues 30. These ASCs with a plasma cell mature phenotype have a potential lifespan of more than one year. Because the different IgG subclasses have a half-life of 3 weeks, the maintenance of antibody titres over long period of time from bone marrow antibody secreting cells is very important 31. Therefore, we examined the ability of bone marrow cells of secreting total and OVA-specific IgG after 6 h of stimulation with OVA by ELISPOT assay. This short incubation period is not enough for the differentiation of memory B cells into ASCs, thus, only actively secreting mature plasma cells can be determined 32. We observed a significant increase in the number of bone marrow cells secreting total IgG, IgG1, IgG2b and OVA-specific IgG and IgG1, in mice intranasally immunized with OVA in combination with pidotimod if compared to mice immunized with OVA alone (Fig. 5A-B) . In contrast, we did not find any statistically significant difference in the number of bone marrow cells secreting OVA-specific IgG2b in immunized mice with OVA alone or in combination with pidotimod. Moreover, we didn't observe any increase in the number of splenocytes secreting total and OVA-specific IgG in C57BL/6 (H-2 b ) mice intranasally immunized with OVA co-administered with pidotimod.
Pidotimod generates in vivo an OVA-specific cytotoxic response.
In order to evaluate the ability of pidotimod to induce specific cytotoxic responses against OVA, splenocytes from naïve mice were collected after 21 days from the last intranasal immunization, stained with CFSE and treated for 1 h with dominant, subdominant and cryptic OVA peptides. Cells were then inoculated in C57BL/6 mice previously immunized intranasally with OVA and pidotimod. As shown in Fig. 6 , the ability of splenocytes of intranasally immunized mice to induce a specific cytotoxic response against cells expressing dominant and cryptic OVA peptides was higher in mice immunized with OVA in combination with pidotimod ( Fig. 6B-C) than in mice immunized with OVA alone. On the other hand no response was seen by inoculating splenocytes treated with subdominant peptide into immunized mice with OVA alone or OVA plus pidotimod .
Discussion
Activation and maturation of DCs have a pivotal impact on immune response. The majority of adjuvants in experimental use today provide signals which the innate immune system vigorously reacts to, resulting in a generalized potentiation of the immune system so that the Ag coadministrated with the adjuvant can be more effectively taken up, processed and presented by the activated DCs. Molecules with immunomodulatory activity and adjuvant properties at the mucosal site are able to enhance humoral and cellular immune responses against co-administered antigens at both mucosal and systemic levels 14,15,16. 
